BIRC5 and neoplasm: Since the anticancer T21 compound potently decreases the protein levels of the antiapoptotic protein called survivin, expression levels of this potential therapeutic target were evaluated in tumor samples from SQCLC patients through both specific qPCR analysis and survivin protein immunodetection (Figure 1A,B).